MUMBAI:
Zydus Cadila
has received tentative approval from USFDA to market Esomeprazole Magnesium Delayed-Release Capsules (US RLD – NEXIUM). It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad, says a company statement.
Esomeprazole belongs to the group of medicines termed as proton pump inhibitors. Esomeprazole reduces the amount of acid secreted by the stomach. The drug is used to treat the symptoms of
gastroesophageal reflux disease
, to reduce the risk of stomach ulcers in some people taking pain medicines, treat patients with stomach infection (Helicobacter pylori) along with certain antibiotics and long-term treatment of conditions where stomach makes too much acid.
The group now has 247 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.
A business journalist with around two decades of experience track...
Read MoreA business journalist with around two decades of experience tracking key consumer-focussed sectors like consumer durables, retail, consumer goods, aviation, automobiles and advertising, as well as economic ministries of the Union government. Now, writes primarily on pharmaceuticals and healthcare, and on issues of consumer interest. Besides also looks at trends that are shaping consumer behaviour and the broad consumer landscape. \nYou can follow Rupali on Twitter@Rupalijee.
Read Less
Start a Conversation
Post comment